Kenneth T. Mills - Sep 13, 2021 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Signature
/s/ Patrick J. Christmas as attorney-in-fact
Stock symbol
RGNX
Transactions as of
Sep 13, 2021
Transactions value $
-$1,561,425
Form type
4
Date filed
9/15/2021, 04:15 PM
Previous filing
Jun 28, 2021
Next filing
Sep 29, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Options Exercise $11.3K +3K +1.07% $3.76* 284K Sep 13, 2021 Direct F1
transaction RGNX Common Stock Sale -$120K -3K -1.06% $40.02 281K Sep 13, 2021 Direct F1
transaction RGNX Common Stock Options Exercise $125K +33.1K +11.8% $3.76* 314K Sep 14, 2021 Direct F1
transaction RGNX Common Stock Options Exercise $1.58K +1.85K +0.59% $0.85* 316K Sep 14, 2021 Direct F1
transaction RGNX Common Stock Sale -$1.58M -35K -11.08% $45.11 281K Sep 14, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Employee Stock Option (Right to Buy) Options Exercise $0 -3K -1.12% $0.00 266K Sep 13, 2021 Common Stock 3K $3.76 Direct F1, F3
transaction RGNX Employee Stock Option (Right to Buy) Options Exercise $0 -33.1K -12.46% $0.00 233K Sep 14, 2021 Common Stock 33.1K $3.76 Direct F1, F3
transaction RGNX Employee Stock Option (Right to Buy) Options Exercise $0 -1.85K -4.67% $0.00 37.8K Sep 14, 2021 Common Stock 1.85K $0.85 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan.
F2 This transaction was executed in multiple trades at prices ranging from $45.00 to $45.55. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The previously granted option, representing a right to purchase a total of 275,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on May 19, 2016, and the balance vested in equal monthly installments over the 36 months thereafter.
F4 The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter.